Sophie Pierrin-Lépinard
Directeur/Membre du Conseil chez ScreenCell SA
Profil
Sophie Pierrin-Lépinard is currently an Investment Director at BNP Paribas Développement SA and a Director at ScreenCell SA. She previously held positions as a Director at Symetis SA, a Non-Executive Director at Antabio SAS, a Member-Management Board at Apoxis SA, and a General Partner at Banexi Ventures Partners SA. She also served as a Managing Partner at Kreaxi SASU.
Dr. Pierrin-Lépinard holds a doctorate degree from Université Fédérale Toulouse Midi-Pyrénées and a graduate degree from ESCP Europe Campus Paris.
Postes actifs de Sophie Pierrin-Lépinard
| Sociétés | Poste | Début |
|---|---|---|
ScreenCell SA
 ScreenCell SA Miscellaneous Commercial ServicesCommercial Services ScreenCell SA provides access to circulating rare cells. It offers rare cell isolation solutions for medical and research applications. The company was founded by Patrizia Paterlini-Brechot, Ian Jones and Christian Brechot on April 11, 2001 and is headquartered in Sarcelles, France. | Directeur/Membre du Conseil | 17/02/2011 |
BNP Paribas Développement SA
 BNP Paribas Développement SA Investment ManagersFinance BNP Paribas Développement SA operates as private equity firm. The company was founded in 1988 and is headquartered in Paris, France. | Private Equity Investor | 01/12/2017 |
Anciens postes connus de Sophie Pierrin-Lépinard
| Sociétés | Poste | Fin |
|---|---|---|
Banexi Ventures Partners SA
 Banexi Ventures Partners SA Investment ManagersFinance Banexi Ventures Partners SA is a Venture Capital firm, a subsidiary of Kreaxi SASU founded in 1983. Banexi Ventures Partners SA is headquartered in Paris. | Directeur/Membre du Conseil | 16/11/2016 |
Apoxis SA
 Apoxis SA Pharmaceuticals: MajorHealth Technology Apoxis SA develops therapeutics for the treatment of cancer and immunological diseases based on the mechanisms underlying apoptosis or cell death. The company particularly focuses on diseases with unmet medical needs and high commercial potential. It's lead product, APO866, is a novel small molecule therapeutic for the treatment of a range of cancers. The product is also being evaluated in a range of cancers in combination with commonly used chemo and radiotherapies in preclinical studies. It's oncology portfolio also includes APO010, a protein therapeutic that was developed using the company’s proprietary multimerization technology. The company is headquartered in Lausanne, Switzerland. | Corporate Officer/Principal | 01/08/2007 |
Antabio SAS
 Antabio SAS Pharmaceuticals: MajorHealth Technology Antabio SAS operates as a biopharmaceutical company which develops drugs for the treatment and prevention of antibiotic-resistant bacterial infections. The firm focuses bacterial disease research, drug design, antibiotic combination testing, and in vitro technology development operations. The company was founded by Marc Lemonnier and Aymeric Dugray on October 15, 2009 and is headquartered in Labege, France. | Directeur/Membre du Conseil | - |
Kreaxi SASU
 Kreaxi SASU Investment ManagersFinance Kreaxi SASU (Kreaxi) is an independent private equity firm born from the merger of Rhône-Alpes Création and Banexi Ventures Partners. The company is headquartered in Paris, France. | Private Equity Investor | - |
| SYMETIS SA | Directeur/Membre du Conseil | - |
Formation de Sophie Pierrin-Lépinard
| Université Fédérale Toulouse Midi-Pyrénées | Doctorate Degree |
| ESCP Europe Campus Paris | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Banexi Ventures Partners SA
Banexi Ventures Partners SA Investment ManagersFinance Banexi Ventures Partners SA is a Venture Capital firm, a subsidiary of Kreaxi SASU founded in 1983. Banexi Ventures Partners SA is headquartered in Paris. | Finance |
Apoxis SA
Apoxis SA Pharmaceuticals: MajorHealth Technology Apoxis SA develops therapeutics for the treatment of cancer and immunological diseases based on the mechanisms underlying apoptosis or cell death. The company particularly focuses on diseases with unmet medical needs and high commercial potential. It's lead product, APO866, is a novel small molecule therapeutic for the treatment of a range of cancers. The product is also being evaluated in a range of cancers in combination with commonly used chemo and radiotherapies in preclinical studies. It's oncology portfolio also includes APO010, a protein therapeutic that was developed using the company’s proprietary multimerization technology. The company is headquartered in Lausanne, Switzerland. | Health Technology |
Symetis SA
 Symetis SA BiotechnologyHealth Technology Symetis SA develops minimally invasive heart valve replacement devices. Its products include ACURATE TA and ACURATE neo. The company was founded by Simon P. Hoerstrup and Gregor Zünd on September 5, 2001 and is headquartered in Ecublens, Switzerland. | Health Technology |
ScreenCell SA
ScreenCell SA Miscellaneous Commercial ServicesCommercial Services ScreenCell SA provides access to circulating rare cells. It offers rare cell isolation solutions for medical and research applications. The company was founded by Patrizia Paterlini-Brechot, Ian Jones and Christian Brechot on April 11, 2001 and is headquartered in Sarcelles, France. | Commercial Services |
Kreaxi SASU
Kreaxi SASU Investment ManagersFinance Kreaxi SASU (Kreaxi) is an independent private equity firm born from the merger of Rhône-Alpes Création and Banexi Ventures Partners. The company is headquartered in Paris, France. | Finance |
BNP Paribas Développement SA
BNP Paribas Développement SA Investment ManagersFinance BNP Paribas Développement SA operates as private equity firm. The company was founded in 1988 and is headquartered in Paris, France. | Finance |
Antabio SAS
Antabio SAS Pharmaceuticals: MajorHealth Technology Antabio SAS operates as a biopharmaceutical company which develops drugs for the treatment and prevention of antibiotic-resistant bacterial infections. The firm focuses bacterial disease research, drug design, antibiotic combination testing, and in vitro technology development operations. The company was founded by Marc Lemonnier and Aymeric Dugray on October 15, 2009 and is headquartered in Labege, France. | Health Technology |
